Aurinia Pharmaceuticals Inc.

Informe acción NasdaqGM:AUPH

Capitalización de mercado: US$998.1m

Aurinia Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Aurinia Pharmaceuticals de 54.6% y 17.6% respectivamente, mientras que el BPA crecerá en un 54.6% al año.

Información clave

54.6%

Tasa de crecimiento de los beneficios

54.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs29.7%
Tasa de crecimiento de los ingresos17.6%
Rentabilidad financiera futuran/a
Cobertura de analistas

Good

Última actualización02 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Recent updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Aurinia Pharmaceuticals Appears Undervalued

Jul 05

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 02

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 18

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

Aurinia Pharma Q2 2022 Earnings Preview

Aug 03

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:AUPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202634711185N/A5
12/31/20252796050727
12/31/20242348-5167
6/30/2024207-50-2-2N/A
3/31/2024191-63-21-20N/A
12/31/2023176-78-34-33N/A
9/30/2023159-77-38-37N/A
6/30/2023160-73-40-39N/A
3/31/2023147-97-65-64N/A
12/31/2022134-108-80-80N/A
9/30/2022129-115-110-116N/A
6/30/202288-157-141-141N/A
3/31/202266-168-151-151N/A
12/31/202146-181-159-158N/A
9/30/202172-156-138-129N/A
6/30/202158-148-125-117N/A
3/31/202151-127-109-101N/A
12/31/202050-103-77-70N/A
9/30/20200-129-104-98N/A
6/30/20200-110-83-82N/A
3/31/20200-102-73-73N/A
12/31/20190-88-64-64N/A
9/30/20190-57-52-52N/A
6/30/20190-52-51-51N/A
3/31/20190-61-50-50N/A
12/31/20180-53-52-52N/A
9/30/20180-53-47-47N/A
6/30/20180-48-44-44N/A
3/31/20180-34N/A-46N/A
12/31/20170-71N/A-41N/A
9/30/20170-76N/A-36N/A
6/30/20170-70N/A-32N/A
3/31/20170-71N/A-23N/A
12/31/20160-23N/A-19N/A
9/30/20160-19N/A-19N/A
6/30/20160-17N/A-20N/A
3/31/20160-14N/A-19N/A
12/31/20150-19N/A-18N/A
9/30/20150-21N/A-16N/A
6/30/20150-13N/A-15N/A
3/31/20150-23N/A-16N/A
12/31/20140-19N/A-17N/A
9/30/20141-15N/A-16N/A
6/30/20141-17N/A-14N/A
3/31/20141-7N/A-10N/A
12/31/20131-3N/A-5N/A
9/30/20130-6N/A-3N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AUPH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que AUPH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que AUPH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (17.6% al año) de AUPH crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 17.6% al año) de AUPH crezcan más despacio que 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de AUPH se prevé que sea elevada dentro de 3 años.


Descubre empresas en crecimiento